Alteration in SB7-H4 Serum Levels and Placental Biomarker Expression After Therapeutic Plasma Exchange in Early-Onset Preeclampsia Patients

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Oct 26

PMID 39456867

Authors

Liyan Duan

Yuyang Ma

Beatrix Reisch

Elina Hadrovic

Pawel Mach

Rainer Kimmig

Michael Jahn

Angela Koninger

Antonella Iannaccone

Alexandra Gellhaus

Affiliations

Soon will be listed here.

Abstract

Therapeutic plasma exchange (TPE) is a widely used treatment for numerous diseases including pregnancy-related conditions. Our prior study on 20 early-onset preeclampsia patients undergoing TPE revealed a significant extension in pregnancy duration and reduced serum levels of sFlt-1, sFlt-1/PlGF, and sEndoglin. Here, we investigated the impact of TPE on serum sB7-H4, an immunological checkpoint molecule, and placental proteins (Flt-1, Eng, B7-H4, iNOS, TNF-α) in TPE-treated early-onset preeclampsia patients (N = 12, 23 + 2-28 + 5 weeks), conventionally treated counterparts (N = 12, 23 + 5-30 weeks), and gestational age-matched controls (N = 8, 22 + 4-31 + 6 weeks). Immunoblotting, ELISA, and co-immunohistochemistry were used for biomarker analysis, including placental inflammation factors (iNOS, TNF-α). The results showed that TPE extended pregnancy by a median of 6.5 days in this cohort of early-onset preeclampsia. Serum sB7-H4, sFlt-1, and sEndoglin levels decreased, along with reduced expression of their membrane-bound proteins in placental tissue upon TPE treatment. Moreover, TPE-treated patients displayed reduced placental inflammation compared to preeclampsia patients receiving standard-of-care treatment. In conclusion, TPE may improve pregnancy outcomes in early-onset preeclampsia by lowering circulating levels of sB7-H4, sFlt-1, and sEndoglin, as well as reducing placental inflammation. This translational approach holds promise for enhancing placental function and extending gestation in high-risk pregnancies including very preterm PE or HELLP cases.

References

Lee J . Conceptual subtleties of the percentile. Int J Epidemiol. 1986; 15(1):141-2. DOI: 10.1093/ije/15.1.141. View

Dittrich E, Schmaldienst S, Langer M, Jansen M, Horl W, Derfler K . Immunoadsorption and plasma exchange in pregnancy. Kidney Blood Press Res. 2002; 25(4):232-9. DOI: 10.1159/000066343. View

Colpo A, Marson P, Pavanello F, Tison T, Gervasi M, Zambon A . Therapeutic apheresis during pregnancy: A single center experience. Transfus Apher Sci. 2019; 58(5):652-658. DOI: 10.1016/j.transci.2019.07.009. View

Fenton T, Kim J . A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013; 13:59. PMC: 3637477. DOI: 10.1186/1471-2431-13-59. View

Choi I, Zhu G, Sica G, Strome S, Cheville J, Lau J . Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol. 2003; 171(9):4650-4. DOI: 10.4049/jimmunol.171.9.4650. View

Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y . Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12(6):642-9. DOI: 10.1038/nm1429. View

Kendall R, Thomas K . Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993; 90(22):10705-9. PMC: 47846. DOI: 10.1073/pnas.90.22.10705. View

Nguyen T, Kahn D, Loewendorf A . Maternal-Fetal rejection reactions are unconstrained in preeclamptic women. PLoS One. 2017; 12(11):e0188250. PMC: 5703473. DOI: 10.1371/journal.pone.0188250. View

Tong S, Kaituu-Lino T, Hastie R, Brownfoot F, Cluver C, Hannan N . Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. Am J Obstet Gynecol. 2020; 226(2S):S1157-S1170. DOI: 10.1016/j.ajog.2020.09.014. View

10.

Cinelli M, Do H, Miley G, Silverman R . Inducible nitric oxide synthase: Regulation, structure, and inhibition. Med Res Rev. 2019; 40(1):158-189. PMC: 6908786. DOI: 10.1002/med.21599. View

11.

Tyson J, Parikh N, Langer J, Green C, Higgins R . Intensive care for extreme prematurity--moving beyond gestational age. N Engl J Med. 2008; 358(16):1672-81. PMC: 2597069. DOI: 10.1056/NEJMoa073059. View

12.

Costa M, Paez A . Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management. Transfus Apher Sci. 2021; 60(3):103164. DOI: 10.1016/j.transci.2021.103164. View

13.

Thomson A, Telfer J, Kohnen G, Young A, Cameron I, Greer I . Nitric oxide synthase activity and localization do not change in uterus and placenta during human parturition. Hum Reprod. 1998; 12(11):2546-52. DOI: 10.1093/humrep/12.11.2546. View

14.

Sibai B, Barton J . Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol. 2007; 196(6):514.e1-9. DOI: 10.1016/j.ajog.2007.02.021. View

15.

Du L, He F, Kuang L, Tang W, Li Y, Chen D . eNOS/iNOS and endoplasmic reticulum stress-induced apoptosis in the placentas of patients with preeclampsia. J Hum Hypertens. 2016; 31(1):49-55. PMC: 5144123. DOI: 10.1038/jhh.2016.17. View

16.

Bisson C, Dautel S, Patel E, Suresh S, Dauer P, Rana S . Preeclampsia pathophysiology and adverse outcomes during pregnancy and postpartum. Front Med (Lausanne). 2023; 10:1144170. PMC: 10060641. DOI: 10.3389/fmed.2023.1144170. View

17.

Radulescu C, Bacarea A, Hutanu A, Gabor R, Dobreanu M . Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia. Mediators Inflamm. 2016; 2016:3027363. PMC: 5069373. DOI: 10.1155/2016/3027363. View

18.

Toporsian M, Gros R, Kabir M, Vera S, Govindaraju K, Eidelman D . A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005; 96(6):684-92. DOI: 10.1161/01.RES.0000159936.38601.22. View

19.

Gubensek J, Ponikvar R, Srsen T, Fabjan Vodusek V, Moertl M, Lucovnik M . Treatment of preeclampsia at extremely preterm gestation with therapeutic plasma exchange. Clin Nephrol. 2021; 96(1):101-106. DOI: 10.5414/CNP96S18. View

20.

El-Haieg D, Zanati M, El-Foual F . Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet. 2007; 99(3):236-41. DOI: 10.1016/j.ijgo.2007.05.045. View